NextCure Inc NXTC:NASDAQ

Last Price$13.12NASDAQ Closing Price as of 3:59PM ET 1/26/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.50(3.67%)
Bid (Size)$13.12 (5)
Ask (Size)$13.15 (2)
Day Low / High$12.91 - 13.95
Volume206.6 K
 

View Biotechnology IndustryPeer Comparison as of 01/26/2021

 

NextCure Inc ( NASDAQ )

Price: $13.12
Change: -0.50 (3.67%)
Volume: 206.6 K
3:59PM ET 1/26/2021
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Trevena Inc ( NASDAQ )

Price: $2.31
Change: -0.03 (1.28%)
Volume: 3.5 M
3:59PM ET 1/26/2021
 
 

Aeglea Bio Therapeutics Inc ( NASDAQ )

Price: $7.38
Change: -0.26 (3.40%)
Volume: 151.6 K
3:59PM ET 1/26/2021
 
 

Ibio Inc ( NYSE MKT LLC )

Price: $1.72
Change: +0.01 (0.58%)
Volume: 17.9 M
6:30PM ET 1/26/2021
 

Read more news Recent News

Analyst Actions: BofA Securities Downgrades NextCure to Underperform From Neutral, Adjusts Price Target to $10 From $13
9:31AM ET 1/15/2021 MT Newswires

NextCure (NXTC) has an average rating of outperform and price targets ranging from $11 to $32, according to analysts polled by Capital IQ. (MT Newswires...

NextCure Hires Dr. Han Myint as Chief Medical Officer
4:11PM ET 1/14/2021 MT Newswires

NextCure (NXTC) said after markets closed Thursday that it has appointed Dr. Han Myint as chief medical officer. Dr. Myint has more than two decades of...

Analyst Actions: Benchmark Upgrades NextCure to Buy From Hold; Price Target is $17
10:46AM ET 7/16/2020 MT Newswires

NextCure (NXTC) has an average hold rating among analysts, with an average price target of $33. (MT Newswires covers equity, commodity and economic...

Analyst Actions: BTIG Cuts NextCure's Price Target to $27 From $61, Keeps at Buy
9:27AM ET 7/14/2020 MT Newswires

NextCure (NXTC) has an average hold rating among analysts, with an average price target of $37. (MT Newswires covers equity, commodity and economic...

View all Commentary and Analysis

What's Next For NextCure
2:03PM ET 8/24/2020 Seeking Alpha

Osmotica's FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma
11:57AM ET 7/13/2020 Seeking Alpha

NextCure (NXTC) Investor Presentation - Slideshow
1:33PM ET 5/29/2020 Seeking Alpha

NextCure (NXTC) Presents At ASCO 2020 - Slideshow
1:33PM ET 5/29/2020 Seeking Alpha

Company Profile

Business DescriptionNextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD. View company web site for more details
Address9000 Virginia Manor Road
Beltsville, Maryland 20705
Phone+1.240.399.4900
Number of Employees44
Recent SEC Filing01/19/20214
President, Chief Executive Officer & DirectorMichael S. Richman
Chief Operating OfficerTimothy Mayer
Chief Financial OfficerSteven P. Cobourn
Chief Scientific OfficerSolomon Langermann

Company Highlights

Price Open$13.72
Previous Close$13.62
52 Week Range$7.91 - 50.76
Market Capitalization$361.5 M
Shares Outstanding27.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/11/2021

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.19
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-131.52%
Return on Equity-10.00%

Analyst Ratings as of 01/15/2021

Buy
4
Overweight
0
Hold
4
Underweight
1
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset